drugset
drugset / Trial / NCT05919264

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264 ↗

Phase 1/2 Recruiting 619 enrolled Parabilis Medicines, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Timeline

Start
2023-05-23
Primary completion
2027-04-01
Completion
2027-08-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — —
Subject FOG-001 Unknown — Intravenous
Subject Leucovorin Small molecule — —
Subject Nivolumab Monoclonal antibody — —
Subject Oxaliplatin Small molecule — —
Subject Trifluridine/tipiracil Unknown — —
Subject fluorouracil Small molecule — —

Indications

adamantinous craniopharyngioma castration-resistant prostate carcinoma classic familial adenomatous polyposis colorectal cancer desmoid tumor endometrial carcinoma hepatocellular carcinoma metastatic malignant neoplasm